The document summarizes a study published in the New England Journal of Medicine that compared the drug dabigatran to warfarin in patients with atrial fibrillation. The Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial recruited over 18,000 patients from 951 centers in 44 countries. Patients were randomly assigned to receive either blinded fixed doses of dabigatran 110 mg or 150 mg twice daily or unblinded adjusted-dose warfarin. The inclusion and exclusion criteria of the study are listed.